Topics / Dermatology

Weekly issue

Dermatology Papers of the Week

The top Dermatology papers of the week: the 20 most important new papers of the past week, ranked by potential impact. A new issue comes out every Monday, covering the previous Monday-to-Sunday week.

Nov 9 - 15, 2026 · Updated

Prefer new papers every day? It's free.Dermatology Daily Papers →
  1. 1
  2. 2
    Repurposed Endogenous Virus-like Vesicles Mediate Dendritic Cell Long-range Antigen Presentation and T Cell Activation for Enhanced Cancer Vaccination

    Here we show that dendritic cells repurpose the virus-like retrotransposon-derived Arc gene to generate endogenous virus-like vesicles (VLVs) that predominantly carry peptide-MHC and high-density co-stimulatory ligands, intensifying and extending antigen presentation.

  3. 3
    NAT10-mediated Acetylation of JunB Drives Melanoma Progression By Enforcing SLC27A1-dependent Lipid Metabolic Reprogramming

    Results We identify NAT10 as a previously unrecognized prognostic acetyltransferase that is aberrantly upregulated in melanoma, where it promotes tumor stemness and metastasis in correlation with poor clinical outcome.

  4. 4
    Tumor-colonizing Bifidobacterium Dentium Promotes Tumor Progression and Chemotherapy Resistance Via MMP3 and GABA-FOXA2-P-gp Axis

    Here, we identify Bifidobacterium dentium (B. dentium ) as a tumor-associated bacterium enriched in fecal samples from patients with melanoma and colorectal cancer (CRC) and detectable in human melanoma and CRC tissues.

  5. 5

Get papers like these the day they come out, not a week later.

Follow this category
  1. 6
    Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study

    We conducted a nationwide matched case-control study in Denmark of incident BP cases diagnosed between 2007 and 2024.

  2. 7
  3. 8
    Use of A C-Met-targeting Aptamer-drug Conjugate for Efficient Therapy in Both Primary and Metastatic Uveal Melanoma

    However, current therapeutic options remain limited by insufficient efficacy and poor vision preservation. Building upon the molecular design of SL1-MMAE, a c-Met-targeting aptamer-drug conjugate (ApDC), here we investigate its potential translational application as a targeted therapeutic strategy for both primary and metastatic UM.

  4. 9
    High-dimensional Flow Cytometry of Peripheral Blood Mononuclear Cells in Prurigo Nodularis Reveals Dysregulation of IL-6 Family Cytokines

    This study identifies monocytes, activated macrophage-like myeloid cells, and IL-6 family cytokines, particularly IL-6, IL-31 and OSM, as key mediators of inflammation in PN.

  5. 10
  6. 11
    Janus Kinase Inhibitors for Severe Alopecia Areata: A Systematic Literature Review and Network Meta-Analysis

    This analysis indirectly compared oral JAKi efficacy for severe AA at weeks 12 and 24, including FDA-approved treatments and upadacitinib, using a systematic literature review and phase 3 upadacitinib trial data.

  7. 12
    Classification of Itch Patterns and Sentiment Analysis in Patients With Atopic Dermatitis: Clustering Analysis of Patient-Reported Data

    This study analyzed real-world, self-reported data from Atopiyo, Japan's largest AD smartphone application (October 2021-October 2024), to explore itch patterns, treatment behaviors, and patient sentiments.

  8. 13
    TWEAK Signaling Drives The Transition from Psoriasis to Atopic Dermatitis-like Inflammation in Paradoxical Eczema

    To define the underlying mechanism, we stimulated immortalized (N-TERT) and primary human keratinocytes and found that TWEAK acted together with IL-13 to drive a T helper 2- and type I interferon-polarized epithelial program that partially recapitulated the keratinocyte signature of PE lesions.

  9. 14
  10. 15
    Bridging The Gap Between Dermatology and Gynecology for Menopausal and Perimenopausal Patients

    The aim of this article was to improve dermatologists' care of the perimenopausal and menopausal patients and strengthen collaboration with gynecology.

  11. 16
    Risk of Cancer in Psoriasis Patients Treated with Biologic Therapy: A BADBIR Cohort Study

    Cancer risk did not differ significantly for IL-12/23i or IL-17i versus TNFi, nor was KC risk elevated for IL-12/23i. This real-world study found no evidence of an increased risk of cancer or KC with biologic compared with non-biologic systemic therapies, or across the biologic classes.

  12. 17
    Bacteriophage-Derived Endolysins in Atopic Dermatitis and Other Pruritic Dermatoses: Mechanistic Rationale, Clinical Evidence, and Limitations

    This review evaluates how endolysins work, the available clinical evidence, and the remaining questions about formulation, patient selection, inflammation caused by rapid bacterial breakdown, and toxins that may remain active after the bacteria are killed.

  13. 18
    Comprehensive Degron Mapping in Human Transcription Factors

    We present examples of compartment-specific degrons and demonstrate that variant effects in transcription factors correlate with degron potency.

  14. 19
    Switching to Tildrakizumab 200 Mg After Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study

    This study aimed to evaluate the clinical effectiveness, patient-reported outcomes, and dose selection associated with switching to tildrakizumab in patients with moderate-to-severe plaque psoriasis after failure of IL-17 inhibitor therapies. In this prospective real-world study, 30 patients who failed a single IL-17 inhibitor were switched to tildrakizumab and followed for 52 weeks.

  15. 20
    Drug Survival of Systemic Therapies for Psoriasis in The Western Japan Psoriasis Registry: 2024 Update

    We analyzed the drug survival of systemic therapies using data from 2251 patients and 4002 treatment episodes recorded in the WJPR between 2018 and 2024.